Sustained Cardiovascular Actions of APJ Agonism During Renin–Angiotensin System Activation and in Patients With Heart Failure

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Circulation: Heart Failure

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCHEARTFAILURE.111.000077PMID 23519586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production

  2011cited by this paper
• Translational promise of the apelin–APJ system

  2010cited by this paper
• Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure

  2010influential reference
• [Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease

  2009cited by this paper
• Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis.

  2008cited by this paper
• Effect of apelin on glomerular hemodynamic function in the rat kidney.

  2008cited by this paper
• Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli.

  2008cited by this paper
• Impaired Heart Contractility in Apelin Gene–Deficient Mice Associated With Aging and Pressure Overload

  2007cited by this paper
• Direct effects of apelin on cardiomyocyte contractility and electrophysiology.

  2007cited by this paper
• Interactions between apelin and angiotensin II on rat portal vein

  2006cited by this paper
• Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system.

  2006cited by this paper
• Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure

  2006cited by this paper
• Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression

  2006cited by this paper
• Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats.

  2005cited by this paper
• The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.

  2005cited by this paper
• Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells.

  2005cited by this paper
• Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure

  2004cited by this paper
• Apelin Has In Vivo Inotropic Effects on Normal and Failing Hearts

  2004cited by this paper
• Regulatory Roles for APJ, a Seven-transmembrane Receptor Related to Angiotensin-type 1 Receptor in Blood Pressure in Vivo*

  2004cited by this paper
• Intra‐arterial vasopressin in the human forearm: pharmacodynamics and the role of nitric oxide

  2003cited by this paper
• Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure.

  2003cited by this paper
• Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility

  2002cited by this paper
• Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans.

  2001cited by this paper
• The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism.

  2001cited by this paper
• Sodium chloride loading does not alter endothelium-dependent vasodilation of forearm vasculature in either salt-sensitive or salt-resistant patients with essential hypertension.

  2001cited by this paper
• Molecular and Functional Characteristics of APJ

  2000cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction.

  1999cited by this paper
• Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I.

  1999cited by this paper
• Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.

  1998cited by this paper
• Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man.

  1997cited by this paper
• Impairment of endothelial function in salt-sensitive hypertension in humans.

  1997cited by this paper
• Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.

  1996cited by this paper
• Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.

  1994cited by this paper
• A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11.

  1993cited by this paper
• Impedance cardiography using the Sramek-Bernstein method: accuracy and variability at rest and during exercise.

  1992cited by this paper
• Effects of subpressor doses of angiotensin II on renal hemodynamics in relation to blood pressure.

  1983cited by this paper
• Edinburgh Research Explorer Vascular effects of apelin in vivo in man

  year unknowncited by this paper

• Beyond Leptin and Adiponectin: The Diverse Roles of Adipokines in the Myocardial Hypertrophic Process and Heart Failure and Their Potential Contribution in Obesity

  2025cites this paper
• Activation of APJ Receptors by CMF-019, But Not Apelin, Causes Endothelium-Dependent Relaxation of Spontaneously Hypertensive Rat Coronary Arteries

  2025cites this paper
• Metabolically stable apelin analogs: development and functional role in water balance and cardiovascular function.

  2025cites this paper
• Assessment of Levels of Apelinergic System Peptides in Serum and Epicardial Adipose Tissue in Patients with Multivessel Coronary Artery Disease Who Underwent Myocardial Revascularisation

  2025cites this paper
• Morphometric and Molecular Interplay in Hypertension-Induced Cardiac Remodeling with an Emphasis on the Potential Therapeutic Implications

  2025cites this paper
• Targeted delivery of apelin using a novel extracellular vesicle platform for pulmonary arterial hypertension treatment.

  2025cites this paper
• Exogenous [Pyr1]apelin-13 prevents bupivacaine-induced cardiotoxicity via the apelin (APJ) receptor

  2025cites this paper
• The Impact of the Apelinergic System on the Cardiovascular System

  2025cites this paper
• Apelin-13 Attenuates Right Ventricular Hypertrophy and Pulmonary Fibrosis in a Monocrotaline Model of Pulmonary Hypertension.

  2025cites this paper
• Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor

  2024cites this paper
• Apelin-13 as a novel diagnostic laboratory biomarker in thromboembolic disorders: a review of literature with prospective insights

  2024cites this paper
• Deciphering endocrine function of adipose tissue and its significant influences in obesity-related diseases caused by its dysfunction.

  2024cites this paper
• The metabolically resistant apelin-17 analog LIT01-196 reduces cardiac dysfunction and remodeling in heart failure after myocardial infarction.

  2024cites this paper
• Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study

  2024cites this paper
• Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats

  2024cites this paper
• Effects of Angiotensin Receptor Blockers on Apelin and Visfatin in Hypertension

  2024cites this paper
• Expression of the apelin receptor, a novel potential therapeutic target, and its endogenous ligands in diverse stem cell populations in human glioblastoma

  2024cites this paper
• Localized apelin-17 analogue-bicelle interactions as a facilitator of membrane-catalyzed receptor recognition and binding.

  2024cites this paper
• The Apelin/APJ System: A Potential Therapeutic Target for Sepsis

  2024cites this paper
• Expanding the apelin receptor pharmacological toolbox using novel fluorescent ligands

  2023cites this paper
• Potential clinical biomarkers and perspectives in diabetic cardiomyopathy

  2023cites this paper
• Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice

  2023cites this paper
• Targeting the apelin system for the treatment of cardiovascular diseases

  2023influential citation
• Is elabela/toddler a poor prognostic marker in heart failure patients?

  2023cites this paper
• Apelin-13: a protective role in vascular diseases.

  2023cites this paper
• Therapeutic potential of apelin and Elabela in cardiovascular disease.

  2023cites this paper
• The role of endothelial cell in cardiac hypertrophy: Focusing on angiogenesis and intercellular crosstalk.

  2023cites this paper
• Design and preparation of N-linked hydroxypyridine-based APJ agonists.

  2022cites this paper
• Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin receptor.

  2022cites this paper
• The microRNA‐204‐5p inhibits APJ signalling and confers resistance to cardiac hypertrophy and dysfunction

  2022cites this paper
• A Review of the Roles of Apelin and ELABELA Peptide Ligands in Cardiovascular Disease, Including Heart Failure and Hypertension

  2022cites this paper
• Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases

  2022cites this paper
• Apelin-Induced Relaxation of Coronary Arteries Is Impaired in a Model of Second-Hand Cigarette Smoke Exposure

  2022cites this paper
• Apelin is expressed throughout the human kidney, is elevated in chronic kidney disease & associates independently with decline in kidney function

  2022cites this paper
• Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists.

  2021cites this paper
• Elabela as a novel marker: Well-correlated with WIfI amputation risk score in lower extremity arterial disease patients

  2021cites this paper
• Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure.

  2021cites this paper
• Apelin and Vasopressin: The Yin and Yang of Water Balance

  2021cites this paper
• Apelin Pathway in Cardiovascular, Kidney, and Metabolic Diseases: Therapeutic role of Apelin Analogs and Apelin Receptor Agonists.

  2021cites this paper
• Identification of 6-​Hydroxy-​5-​phenyl​sulfonylpyrimidin-​4(1H)​-​one APJ Receptor Agonists.

  2021cites this paper
• The therapeutic potential of apelin in kidney disease

  2021cites this paper
• Apelin improves cardiac function mainly through peripheral vasodilation in a mouse model of dilated cardiomyopathy.

  2021cites this paper
• Biased Agonism: Renewing GPCR’s Targetability for the Drug Discovery

  2021cites this paper
• The therapeutic potentials of apelin in obesity-associated diseases.

  2021cites this paper
• The emerging role of the apelinergic system in kidney physiology and disease.

  2021cites this paper
• Pyrazole Agonist of the Apelin Receptor Improves Symptoms of Metabolic Syndrome in Mice.

  2021cites this paper
• Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate.

  2021cites this paper
• In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure

  2021cites this paper
• Elabela as a novel marker: Well-correlated with WIfI amputation risk score in lower extremity arterial disease patients.

  2021cites this paper
• Apelin Inhibits an Endothelium-Derived Hyperpolarizing Factor-Like Pathway in Rat Cerebral Arteries.

  2020cites this paper
• Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications.

  2020cites this paper
• Are the Clinical Presentations (Phenotypes) of Gitelman’s and Bartter’s Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their “pH” Enotype?

  2020cites this paper
• [MeArg1, NLe10]-apelin-12: Optimization of solid-phase synthesis and evaluation of biological properties in vitro and in vivo.

  2020cites this paper
• Discovery and SAR of aryl hydroxy pyrimidinones as potent small molecule agonists of the GPCR APJ.

  2020cites this paper
• Apelin-13 Inhibits Methylglyoxal-Induced Unfolded Protein Responses and Endothelial Dysfunction via Regulating AMPK Pathway

  2020cites this paper
• APELİNERJİK SİSTEM ve MİYOKARDİYAL KONTRAKTİLİTE

  2020cites this paper
• Identification and Development of AMG 986: A Potent and Efficacious APJ Agonist for the Treatment of Heart Failure

  2020cites this paper
• Distinct hemodynamic responses to (Pyr)Apelin-13 in large animal models.

  2020cites this paper
• Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure

  2020cites this paper
• Increased apelin receptor gene expression in the subfornical organ of spontaneously hypertensive rats

  2020cites this paper
• Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system

  2020cites this paper
• Cardiovascular response to small molecule APJ activation.

  2020cites this paper
• Biphenyl Acid Derivatives as APJ Receptor Agonists.

  2019cites this paper
• Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.

  2019cites this paper
• Cardioprotective apelin effects and the cardiac-renal axis: review of existing science and potential therapeutic applications of synthetic and native regulated apelin

  2019cites this paper
• The apelin/APJ system as a therapeutic target in metabolic diseases

  2019cites this paper
• The Identification and Pharmacological Characterisation of Novel Apelin Receptor Agonists In Vitro and In Vivo

  2019cites this paper
• [The functional role of endogenous APJ agonists; Apelin and Elabela/Toddler in cardiovascular diseases].

  2019cites this paper
• Systemic Outcomes of (Pyr1)-Apelin-13 Infusion at Mid-Late Pregnancy in a Rat Model with Preeclamptic Features

  2019cites this paper
• The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders

  2019cites this paper
• The apelinergic-axis in human preeclamptic pregnancies: A systematic review.

  2019cites this paper
• International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand

  2019cites this paper
• Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis

  2019cites this paper
• New drugs in preclinical and early stage clinical development in the treatment of heart failure

  2018influential citation
• Blockade of Rostral Ventrolateral Medulla Apelin Receptors Does Not Attenuate Arterial Pressure in SHR and L-NAME-Induced Hypertensive Rats

  2018cites this paper
• Elabela, a newly discovered APJ ligand: Similarities and differences with Apelin

  2018cites this paper
• Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension

  2018cites this paper
• Gender-specific association between Apelin/APJ gene polymorphisms and hypertension risk in Southeast China.

  2018cites this paper
• Vascular effects of apelin: Mechanisms and therapeutic potential

  2018cites this paper
• Regulation of Vascular Tone in Cerebral and Coronary Arteries by Apelin/APJ Receptor Mechanisms

  2018cites this paper
• Apelin Reduces Nitric Oxide–Induced Relaxation of Cerebral Arteries by Inhibiting Activation of Large-Conductance, Calcium-Activated K Channels

  2018cites this paper
• Hepatic and cardiac beneficial effects of a long‐acting Fc‐apelin fusion protein in diet‐induced obese mice

  2018cites this paper
• Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology

  2018cites this paper
• Activation of Large Conductance, Calcium-Activated Potassium Channels by Nitric Oxide Mediates Apelin-Induced Relaxation of Isolated Rat Coronary Arteries

  2018influential citation
• Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic‐euglycaemic clamp

  2018cites this paper
• The right ventricle in heart failure with preserved ejection fraction

  2018cites this paper
• [Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13

  2017influential citation
• Apelinergic System Structure and Function.

  2017cites this paper
• Adipokines and cardiovascular disease: A comprehensive review.

  2017cites this paper
• The role of apelin in the pulmonary circulation

  2017cites this paper
• Current evidence-based therapy does not restore plasma apelin level in phenotypically diverse chronic heart failure patients

  2017cites this paper
• Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases.

  2017cites this paper
• Beneficial Effects of Apelin on Vascular Function in Patients With Central Obesity

  2017cites this paper
• Apelin/APJ system: A bifunctional target for cardiac hypertrophy.

  2017cites this paper
• Impact of CT-apelin and NT-proBNP on identifying non-responders to cardiac resynchronization therapy

  2017cites this paper
• Endothelial and Perivascular Adipose Tissue Abnormalities in Obesity-Related Vascular Dysfunction: Novel Targets for Treatment.

  2017cites this paper
• Synthetic Modification within the "RPRL" Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation.

  2017cites this paper
• Development of original metabolically stable apelin‐17 analogs with diuretic and cardiovascular effects

  2017cites this paper
• Discovery of a novel small molecule agonist scaffold for the APJ receptor.

  2016cites this paper
• Apelin-13 infusion salvages the peri-infarct region to preserve cardiac function after severe myocardial injury.

  2016cites this paper